ストックスクリーナーアプリを入手
22.50
5.58%
1.19
アフターアワーズ：
22.53
0.03
+0.13%
Sutro Biopharma Inc (STRO) 最新ニュース
Sutro Biopharma Hits New 52-Week High of $20.93, Up 431.69% - Markets Mojo
Sutro Biopharma Hits New 52-Week High of $20.48, Up 431.69% - Markets Mojo
Sutro Biopharma Hits New 52-Week High of $21.40, Soars 453% - Markets Mojo
Sutro Biopharma (STRO) to Release Quarterly Earnings on Thursday - Defense World
Sutro Biopharma: Transformed leadership and advanced ADC pipeline drive clinical progress, with key data due mid-year - TradingView
Sutro Biopharma: Transformed leadership and advanced ADC platform drive rapid clinical progress and innovation - TradingView
Sutro Biopharma (STRO) GC reports new RSUs, options and tax share withholdings - Stock Titan
Sutro Biopharma (NASDAQ: STRO) CSO receives RSUs and options - Stock Titan
Sutro Biopharma (STRO) CFO awarded 40,000 options and 5,000 RSUs - Stock Titan
Sutro Biopharma (STRO) CEO receives RSU and option grants, shares withheld for taxes - Stock Titan
174,843 Shares in Sutro Biopharma, Inc. $STRO Purchased by GSA Capital Partners LLP - MarketBeat
Sutro Biopharma, Inc. (STRO) Presents at 16th Annual World ADC London SummitSlideshow - Seeking Alpha
STRO PE Ratio & Valuation, Is STRO Overvalued - Intellectia AI
STRO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sutro Biopharma to participate in key investor conferences - Traders Union
Sutro Biopharma to Participate in Upcoming Investor Conferences - marketscreener.com
Sutro Biopharma Announces Participation at the 16th World ADC London Summit - The Manila Times
World ADC London panels spotlight Sutro Biopharma’s dual-payload ADCs - Stock Titan
Earnings Miss: Is Sutro Biopharma Inc a stock for growth or value investors2025 Key Highlights & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Is Sutro Biopharma Inc. a stock for growth or value investorsQuarterly Portfolio Report & Accurate Buy Signal Notifications - mfd.ru
Is Sutro Biopharma Inc. in a bullish channelTrend Reversal & Low Drawdown Trading Strategies - mfd.ru
Levels Update: Should I invest in Sutro Biopharma Inc before earningsEarnings Overview Report & High Yield Equity Trading Tips - baoquankhu1.vn
Is Sutro Biopharma Inc. (S09) stock a contrarian opportunity2025 Macro Impact & Real-Time Chart Breakout Alerts - mfd.ru
STRO Technical Analysis & Stock Price Forecast - Intellectia AI
Suvretta Capital exits Sutro Biopharma (STRO), reports 0% beneficial stake - Stock Titan
Sutro Biopharma prices $110M common stock offering - MSN
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains? - Yahoo Finance
Jobs Data: Can Sutro Biopharma Inc deliver alpha2025 Market Outlook & Weekly Breakout Watchlists - baoquankhu1.vn
Sutro Biopharma prices $110 million common stock offering By Investing.com - Investing.com Nigeria
Performance Recap: Why is Sutro Biopharma Inc stock going downJuly 2025 Setups & Long-Term Capital Growth Strategies - baoquankhu1.vn
Sutro Biopharma Highlights ADC Platform in New Presentation - TipRanks
Sutro Biopharma Signs Underwriting Agreement With Leerink Partners and TD Securities (USA) - TradingView
Sutro Biopharma Stock Rises 8% After Announcement Of Pricing Of 7.9 Mln Shares - Nasdaq
Sutro Biopharma Prices $110 Mln Underwritten Offering; Stock Jumps 18% - RTTNews
Sutro Biopharma (STRO) Sees Joint Management in Upcoming Offerin - GuruFocus
Sutro Biopharma prices $110 million common stock offering - Investing.com
Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering - Yahoo Finance
Sutro Biopharma, Inc. (NASDAQ:STRO) has caught the attention of institutional investors who hold a sizeable 41% stake - Yahoo Finance
Aug Sectors: Why is Sutro Biopharma Inc stock going downTrade Risk Summary & Stock Portfolio Risk Management - baoquankhu1.vn
Here's Why We're A Bit Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Situation - Sahm
Short Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Expands By 30.5% - MarketBeat
Pullback Watch: Is Sutro Biopharma Inc in a bullish channelWeekly Gains Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Macro Review: Should I invest in Sutro Biopharma Inc before earningsTrade Volume Summary & Weekly High Potential Alerts - baoquankhu1.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Options Flow: Is Sutro Biopharma Inc affected by consumer sentimentJuly 2025 Decliners & Risk Managed Investment Signals - baoquankhu1.vn
Sutro Biopharma (STRO) soars 5.9%: Is further upside left in the stock? - MSN
Winners Losers: Does MFS Government Markets Income Trust have a sustainable dividendEntry Point & Short-Term Trading Alerts - baoquankhu1.vn
Trade Recap: Is Adlai Nortye Ltd Depositary Receipt part of any ETF2025 Geopolitical Influence & Reliable Price Breakout Alerts - baoquankhu1.vn
Panic Selling: Is Sutro Biopharma Inc affected by consumer sentimentJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Sutro Biopharma (NASDAQ:STRO) Upgraded to “Market Outperform” at Citizens Jmp - Defense World
STRO Receives Upgraded Analyst Rating from Citizens | STRO Stock News - GuruFocus
Sutro Biopharma (NASDAQ:STRO) Raised to "Market Outperform" at Citizens Jmp - MarketBeat
Citizens Upgrades Sutro Biopharma (STRO) - Nasdaq
Citizens JMP Upgrades Sutro Biopharma(STRO.US) to Buy Rating, Announces Target Price $23 - 富途牛牛
Citizens upgrades Sutro Biopharma stock rating to Market Outperform By Investing.com - Investing.com Canada
Sutro Biopharma, Inc. (NASDAQ:STRO) Short Interest Down 27.8% in December - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO) and Molina Healthcare (MOH) - The Globe and Mail
BofA Securities Maintains Sutro Biopharma(STRO.US) With Sell Rating, Maintains Target Price $8 - 富途资讯
Aug Decliners: Is Sutro Biopharma Inc stock a value trapQuarterly Portfolio Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Sutro Biopharma: Streamlined strategy and advanced ADC pipeline drive clinical progress and differentiation - TradingView — Track All Markets
Sutro Biopharma: Accelerated ADC pipeline and strategic focus drive clinical progress and financial stability - TradingView — Track All Markets
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):